ADIPOR2

Summary

ADIPOR2 (adiponectin receptor 2, HGNC:24041) is a protein-coding gene on chromosome 12p13.33, encoding Adiponectin receptor protein 2 (Q86V24). Receptor for ADIPOQ, an essential hormone secreted by adipocytes that regulates glucose and lipid metabolism.

The adiponectin receptors, ADIPOR1 (MIM 607945) and ADIPOR2, serve as receptors for globular and full-length adiponectin (MIM 605441) and mediate increased AMPK (see MIM 602739) and PPAR-alpha (PPARA; MIM 170998) ligand activities, as well as fatty acid oxidation and glucose uptake by adiponectin (Yamauchi et al., 2003 [PubMed 12802337]).

Source: NCBI Gene 79602 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 71 total — 22 pathogenic, 1 likely-pathogenic
• GTEx eGene: eQTL in 15 tissues, sQTL in 16 (q < 0.05)
• Constraint (gnomAD): pLI 0.18 (intermediate), LOEUF 0.64 (unconstrained)
• MANE Select transcript: NM_024551
• Notable: 71 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24041
Approved symbol	ADIPOR2
Name	adiponectin receptor 2
Location	12p13.33
Locus type	gene with protein product
Status	Approved
Aliases	PAQR2, ACDCR2
Ensembl gene	ENSG00000006831
Ensembl biotype	protein_coding
OMIM	607946
Entrez	79602

Gene structure

Transcript identifiers

Ensembl transcripts: 58 — 42 protein_coding, 10 nonsense_mediated_decay, 6 protein_coding_CDS_not_defined

MANE Select: ENST00000357103

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 2, TSL 3: 3, TSL 4: 1

ENST00000357103, ENST00000535774, ENST00000537190, ENST00000537545, ENST00000540974, ENST00000543456, ENST00000544470, ENST00000878963, ENST00000878964, ENST00000878965, ENST00000878966, ENST00000878967, ENST00000878968, ENST00000878969, ENST00000878970, ENST00000878971, ENST00000878972, ENST00000878973, ENST00000878974, ENST00000878975, ENST00000878976, ENST00000878977, ENST00000878978, ENST00000878979, ENST00000878980, ENST00000878981, ENST00000878982, ENST00000878983, ENST00000878984, ENST00000878985, ENST00000878986, ENST00000878987, ENST00000878988, ENST00000878989, ENST00000878990, ENST00000878991, ENST00000878992, ENST00000878993, ENST00000878994, ENST00000878995, ENST00000878996, ENST00000924874, ENST00000924875, ENST00000924876, ENST00000924877, ENST00000924878, ENST00000969120, ENST00000993732, ENST00000993733, ENST00000993734, ENST00000993735, ENST00000993736, ENST00000993737, ENST00000993738, ENST00000993739, ENST00001060126, ENST00001060127, ENST00001141126

RefSeq mRNA: 4 — MANE Select: NM_024551 NM_001375363, NM_001375364, NM_001375365, NM_024551

CCDS: CCDS8511

Canonical transcript exons

ENST00000357103 — 8 exons

Exon	Start	End
ENSE00000712257	1783880	1784073
ENSE00000816807	1780451	1780637
ENSE00000816808	1780889	1781076
ENSE00001402644	1785944	1788674
ENSE00001426014	1691070	1691191
ENSE00003468776	1754258	1754514
ENSE00003512544	1777854	1778025
ENSE00003616430	1772842	1772961

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 97.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.9067 / max 536.2809, expressed in 1822 samples.

Highest expression (Bgee): corpus callosum, C1 segment of cervical spinal cord, adrenal gland cortex, lung, adrenal gland.

Genetic regulation across tissues (GTEx eQTL / sQTL)

ADIPOR2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 15 tissues and its splicing (sQTL) in 16 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 31 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	sqtl	4.8e-18	-0.53	12:1710393:A:C
Testis	sqtl	1.7e-15	+0.90	12:1749575:G:A
Whole Blood	eqtl	1.3e-11	+0.28	12:1668968:A:G
Cells EBV-transformed lymphocytes	sqtl	2.1e-09	-0.78	12:1732977:G:C
Thyroid	eqtl	1.9e-08	+0.30	12:1672523:T:A
Muscle Skeletal	eqtl	3.2e-07	-0.16	12:1722189:G:A
Esophagus Mucosa	eqtl	5.2e-07	+0.12	12:1732977:G:C
Esophagus Mucosa	sqtl	7.7e-07	-0.34	12:1777477:C:T
Colon Sigmoid	eqtl	1.4e-06	+0.21	12:1766599:A:G
Nerve Tibial	sqtl	1.6e-06	+0.34	12:1724746:G:A
Adipose Visceral Omentum	sqtl	7.7e-06	-0.38	12:1749553:G:A
Lung	sqtl	2.5e-04	+0.31	12:1751375:G:A
Prostate	sqtl	6.8e-04	+2.59	12:872270:C:T
Nerve Tibial	eqtl	9.5e-04	+0.14	12:1746794:C:G
Adipose Subcutaneous	sqtl	1.7e-03	-0.31	12:1754562:A:T
Skin Sun Exposed Lower leg	sqtl	3.3e-03	-0.30	12:1722189:G:A
Cells Cultured fibroblasts	eqtl	3.7e-03	+0.14	12:1792380:A:C
Minor Salivary Gland	eqtl	4.4e-03	-0.27	12:1799266:C:T
Brain Cerebellum	sqtl	4.7e-03	-1.83	12:1498192:G:A
Pituitary	eqtl	5.2e-03	-0.16	12:1748255:A:T

FANTOM5 promoters

4 alternative TSS:

Promoter ID	TPM avg	Samples expressed
123384	37.2788	1822
123391	0.4146	187
123390	0.1476	60
123389	0.0657	26

Top tissues by expression

showing 100 of 134 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus callosum	UBERON:0002336	97.84	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.64	gold quality
right adrenal gland cortex	UBERON:0035827	96.88	gold quality
right lung	UBERON:0002167	96.65	gold quality
right adrenal gland	UBERON:0001233	96.50	gold quality
left adrenal gland	UBERON:0001234	96.12	gold quality
left adrenal gland cortex	UBERON:0035825	96.04	gold quality
substantia nigra	UBERON:0002038	95.96	gold quality
adrenal gland	UBERON:0002369	95.92	gold quality
lower esophagus mucosa	UBERON:0035834	95.77	gold quality
liver	UBERON:0002107	95.35	gold quality
colonic epithelium	UBERON:0000397	95.34	gold quality
adrenal tissue	UBERON:0018303	95.21	gold quality
Ammon’s horn	UBERON:0001954	94.54	gold quality
duodenum	UBERON:0002114	94.52	gold quality
tibial nerve	UBERON:0001323	94.46	gold quality
omental fat pad	UBERON:0010414	94.45	gold quality
adipose tissue	UBERON:0001013	94.44	gold quality
right lobe of liver	UBERON:0001114	94.38	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.33	gold quality
amygdala	UBERON:0001876	94.02	gold quality
temporal lobe	UBERON:0001871	93.99	gold quality
putamen	UBERON:0001874	93.87	gold quality
body of stomach	UBERON:0001161	93.70	gold quality
rectum	UBERON:0001052	93.67	gold quality
upper lobe of left lung	UBERON:0008952	93.65	gold quality
stomach	UBERON:0000945	93.46	gold quality
thoracic mammary gland	UBERON:0005200	93.37	gold quality
lung	UBERON:0002048	93.23	gold quality
skeletal muscle tissue	UBERON:0001134	93.17	gold quality
mucosa of transverse colon	UBERON:0004991	93.09	gold quality
esophagus mucosa	UBERON:0002469	93.00	gold quality
hypothalamus	UBERON:0001898	92.98	gold quality
ventricular zone	UBERON:0003053	92.86	gold quality
islet of Langerhans	UBERON:0000006	92.61	gold quality
bone marrow cell	CL:0002092	92.60	gold quality
muscle tissue	UBERON:0002385	92.58	gold quality
caudate nucleus	UBERON:0001873	92.55	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.52	gold quality
muscle of leg	UBERON:0001383	92.35	gold quality
gastrocnemius	UBERON:0001388	92.31	gold quality
fundus of stomach	UBERON:0001160	92.26	gold quality
transverse colon	UBERON:0001157	92.22	gold quality
pancreas	UBERON:0001264	92.22	gold quality
body of pancreas	UBERON:0001150	92.09	gold quality
esophagus	UBERON:0001043	92.02	gold quality
small intestine	UBERON:0002108	91.76	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.75	gold quality
intestine	UBERON:0000160	91.58	gold quality
monocyte	CL:0000576	91.49	gold quality
leukocyte	CL:0000738	91.48	gold quality
colon	UBERON:0001155	91.47	gold quality
primary visual cortex	UBERON:0002436	91.46	gold quality
ganglionic eminence	UBERON:0004023	91.34	gold quality
skin of leg	UBERON:0001511	91.26	gold quality
multicellular organism	UBERON:0000468	91.25	gold quality
zone of skin	UBERON:0000014	91.19	gold quality
skin of abdomen	UBERON:0001416	91.04	gold quality
thyroid gland	UBERON:0002046	90.98	gold quality
cerebral cortex	UBERON:0000956	90.91	gold quality
heart left ventricle	UBERON:0002084	90.90	gold quality
brain	UBERON:0000955	90.89	gold quality
left lobe of thyroid gland	UBERON:0001120	90.86	gold quality
smooth muscle tissue	UBERON:0001135	90.85	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.85	gold quality
vagina	UBERON:0000996	90.81	gold quality
right testis	UBERON:0004534	90.79	gold quality
lower esophagus	UBERON:0013473	90.76	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.74	gold quality
right atrium auricular region	UBERON:0006631	90.70	gold quality
adenohypophysis	UBERON:0002196	90.64	gold quality
heart	UBERON:0000948	90.60	gold quality
nucleus accumbens	UBERON:0001882	90.58	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.53	gold quality
tonsil	UBERON:0002372	90.52	gold quality
right lobe of thyroid gland	UBERON:0001119	90.45	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.39	gold quality
body of uterus	UBERON:0009853	90.36	gold quality
testis	UBERON:0000473	90.35	gold quality
left testis	UBERON:0004533	90.30	gold quality
granulocyte	CL:0000094	90.25	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.25	gold quality
stromal cell of endometrium	CL:0002255	90.22	gold quality
mucosa of stomach	UBERON:0001199	90.21	gold quality
prefrontal cortex	UBERON:0000451	90.19	gold quality
frontal cortex	UBERON:0001870	90.18	gold quality
right frontal lobe	UBERON:0002810	90.16	gold quality
bone marrow	UBERON:0002371	90.15	gold quality
ovary	UBERON:0000992	90.09	gold quality
left uterine tube	UBERON:0001303	90.07	gold quality
myometrium	UBERON:0001296	90.03	gold quality
anterior cingulate cortex	UBERON:0009835	90.02	gold quality
left ovary	UBERON:0002119	89.90	gold quality
placenta	UBERON:0001987	89.87	gold quality
pituitary gland	UBERON:0000007	89.76	gold quality
ectocervix	UBERON:0012249	89.64	gold quality
right ovary	UBERON:0002118	89.63	gold quality
apex of heart	UBERON:0002098	89.61	gold quality
vermiform appendix	UBERON:0001154	89.52	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.50	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.77

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 79 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Spinal cord	tissue	75.3
Corpus callosum	tissue	58.8
Midbrain	tissue	54.6
Medulla oblongata	tissue	53.2
Substantia nigra	tissue	53.2
Liver	tissue	49.4	not detected
Thalamus	tissue	44.9
Caudate putamen	tissue	43.2
Superior colliculi	tissue	41.5
Pons	tissue	40.3
Periaqueductal gray	tissue	34.9
Adipose tissue	tissue	33.6	not detected
Nucleus accumbens	tissue	29.3
Vagina	tissue	28.4	low
Frontal cortex	tissue	27.9
Locus coeruleus	tissue	27.7
Pancreas	tissue	27.5	medium
Adrenal gland	tissue	27.2	medium
Hypothalamus	tissue	26.6
Putamen	tissue	26.3
Stomach 1	tissue	25.5	medium
Pituitary gland	tissue	25.4
Ventral forebrain	tissue	25.4
Hippocampus	tissue	23.5	not detected
Hippocampal formation	tissue	23.1
Septum	tissue	22.6
Skeletal muscle	tissue	22.1	medium
Cerebral cortex	tissue	21.7	not detected
Somatosensory cortex	tissue	21.7
Duodenum	tissue	20.9	medium
Motor cortex	tissue	20.6
Esophagus	tissue	19.9	low
Prefrontal cortex	tissue	19.7
Occipital cortex	tissue	19.6
Temporal cortex	tissue	18.9
Amygdala	tissue	18.8
Entorhinal cortex	tissue	18.8
Basal ganglia	tissue	18.7	low
Postcentral gyrus	tissue	18.7
Tongue	tissue	18.5
Small intestine	tissue	18.5	medium
Cerebellum	tissue	18.4	not detected
Retrosplenial and cingulate cortex	tissue	18.0
Retrosplenial cortex	tissue	18.0
Insular cortex	tissue	18.0
Olfactory bulb	tissue	17.0
Thyroid gland	tissue	16.9	medium
Rectum	tissue	16.7	medium
Choroid plexus	tissue	16.1
Colon	tissue	16.0	medium
Parathyroid gland	tissue	15.9	not detected
Testis	tissue	14.5	low
Breast	tissue	13.5	not detected
Lung	tissue	12.4	not detected
Heart muscle	tissue	12.2	medium
Placenta	tissue	12.2	high
Retina	tissue	12.1
Skin 1	tissue	11.9	medium
Ovary	tissue	11.9	not detected
Thymus	tissue	11.9

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Parieto-temporal junction (white matter) (93.4), Corpus callosum, genu (white matter) (84.7), Cerebellar white matter (83.9), Temporal white matter (77.7), Ventral spinal cord (75.3).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF3, FOXO1, NR3C1, PPARG

miRNA regulators (miRDB)

Targeting ADIPOR2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 184 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4775	99.98	75.00	6394
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-34C-5P	99.97	70.45	1577

Functional genomics

gnomAD constraint: pLI 0.176, LOEUF 0.636, missense Z 3.52 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000357103 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
12:1,754,344–1,772,872	65 / 79.9	0.81	no
12:1,772,873–1,781,049	112 / 249.5	0.45	no
12:1,781,050–1,786,069	106 / 149.7	0.71	no

Literature-anchored findings (GeneRIF, showing 40)

• cloning of cDNAs encoding adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2) by expression cloning [AdipoR1 & AdipoR2] (PMID:12802337)
• Here we report the marked expression of mRNAs for the adiponectin receptors AdipoR1 and AdipoR2 in human and rat pancreatic beta cells, at levels similar to liver and greater than muscle. (PMID:14651988)
• Epression levels of AdipoRw as well as plasma adiponectin concentration were lower in people with a family history of Type 2. (PMID:15105989)
• myotube mRNA levels of both receptors are associated with distinct metabolic functions but not with insulin sensitivity; AdipoR1, but not AdipoR2, expression correlated with insulin secretion. (PMID:15331527)
• a link between adiponectin and bone homeostasis by demonstrating transcription, translation, and secretion of adiponectin, as well as expression of its receptors, AdipoR1 and AdipoR2, in bone-forming cells (PMID:15454091)
• Plasma adiponection and adiponectin receptor 1 and 2 mRNA expression in muscle are not acutely regulated by adipose tissue lipolysis and/or plasma FFA. Adiponectin is abundantly expressed in muscle and is present in/on sarcolemma of muscle fibres. (PMID:15757860)
• Genetic variations in ADIPOR2 are unlikely to lead to a common genetic predisposition to insulin resistance or type 2 diabetes in the Japanese population. (PMID:15918014)
• Evidence for association between variation in the adiponectin receptor 2 and type 2 diabetes among Amish. (PMID:15983228)
• In patients with chronic hepatitis c, adiponectin and receptors(AdipoR1 and AdipoR2)play a role in hepatic inflammation in both sexes and liver steatosis in males. (PMID:16139921)
• adiponectin receptors have roles in the human endometrium (PMID:16601138)
• Rosiglitazone can elevate the expression of ADIPOR2 in hepatocytes which caninteract functionally with a glucocorticoid receptor in the ADIPOR2 promoter to mediate stimulation of transcription. (PMID:16609881)
• Here we show that MCF-7 cells express adiponectin receptors and respond to human recombinant adiponectin by reducing their growth, AMPkinase activation, and p42/p44 MAPkinase (PMID:16678125)
• 3 variants were found: (+795G/A, +870C/A & +963C/T) in linkage disequilibrium (r2 = 1) with a minor allele frequency of 0.125. This haplotype had higher plasma adiponectin levels & lower fasting triglyceride, VLDL-triglyceride & VLDL-cholesterol levels. (PMID:16700915)
• may contribute to the molecular association between obesity and prostate cancer through a complex interaction with other hormones and cytokines that also play important roles in the pathophysiology of obesity and prostate cancer. (PMID:16899222)
• Upregulated in insulin-resistant women with polycystic ovary syndrome. (PMID:17001470)
• Reduced circulating adiponectin occurs in rat fatty liver disease, but it is elevated in a mouse cirrhosis with similar findings in humans. Diminished hepatic expression of adiponectin receptors (AdipoR2 and AdipoR1) was only found in liver cirrhosis. (PMID:17006986)
• We observed the expression of adiponectin, AdipoR1 and AdipoR2 in the MG-63 cell line and the osteoblastic cell line differentiated from human mesenchymal stem cells. (PMID:17054465)
• AdipoR1 and AdipoR2 are integral membrane proteins with the predicted topology–an intracellular N-terminus and an extracellular C-terminus (PMID:17118803)
• possibility that adiponectin might modulate the growth of normal breast epithelial cells and breast cancer cells directly through AdipoR1 and AdipoR2 receptors (PMID:17123704)
• Genetic variation in ADIPOR2 is not a major cause of extreme insulin resistance in humans, nor does it contribute in a significant manner to type 2 diabetes risk and related traits in UK Europid populations. (PMID:17216283)
• No support for a relation between ADIPOR2 variability and risk of type 2 diabetes in women. (PMID:17416799)
• Plasma adiponectin and muscle gene expression of its specific receptors are controlled by genetic and several specific nongenetic factors (PMID:17426101)
• Adiponectin negatively regulates the progression of gastric cancer cells possibly through AdipoR2. (PMID:17459059)
• Lower AdipoR after kidney transplantation may be secondary to immunosuppression and/or an improvement in glomerular filtration rate and the uremic milieu. (PMID:17697862)
• role of polymorphisms in the adiponectin receptor 1 and 2 genes (ADIPOR1 and ADIPOR2) in insulin resistance and type 2 diabetes [review] (PMID:17716299)
• +33371 A/G polymorphism is associated with increased risk of T2DM and multiple insulin resistance-related phenotypes (including fasting plasma glucose, fasting serum triglycerides, and BMI) in the Chinese population (PMID:18075289)
• evated ADIPOR2 expression is associated with colorectal carcinomas but not in gastrointestinal stromal tumors (PMID:18310295)
• Dexamethasone inhibits AdipoR2 mRNA expression in nondiabetic subjects. (PMID:18363889)
• None of the SNPs in either ADIPOR1 or ADIPOR2 were associated with the risk of type 2 diabetes in Koreans. SNPs of ADIPOR2 were associated with waist circumference. (PMID:18466348)
• Expression of AIDIPOR2 was determined in livers of morbidly obese patients with non-alcoholic fatty liver disease. (PMID:18713296)
• ADIPOR2 SNPs are associated with liver function tests in T2DM subjects, suggesting a possible role of this receptor in liver dysfunction associated with insulin resistance. (PMID:18719649)
• In a HEK293 cell model, we found that downregulating AdipoR1/R2 simultaneously, but not individually, by RNA interference attenuated adiponectin-induced ERK1/2 activation, suggesting that either receptor was sufficient to mediate the response. (PMID:18842004)
• AdipoR2 is overexpressed in liver in obese patients with nonalcoholic steatohepatitis. (PMID:18923878)
• Upregulation in endothelial cells potentiates the antiinflammatory effect of adiponectin, which may apply to cardiovascular complcation in diabetes. (PMID:18988888)
• The lack of correlation between changes in SAT adiponectin gene and protein expression and its circulating levels suggests that adipose tissue synthesis and release of adiponectin are highly regulated pathways. (PMID:18996753)
• In whites, six SNPs in ADIPOQ, one SNP in ADIPOR1 and one SNP in ADIPOR2 were associated with insulin sensitivity at the P<0.05 level. (PMID:19037660)
• Pancreatic cancer expresses adiponectin receptor2 and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study (PMID:19051043)
• The distribution of adiponectin receptors on human peripheral blood mononuclear cells. (PMID:19120283)
• Genetic variation, particularly in the ADIPOR2 gene, contributes to variation in hepatic fat accumulation in humans (PMID:19208777)
• Expression of Adipo-R2, but not Adipo-R1, is observed in the cytoplasm of both placental cytotrophoblasts and syncytiotrophoblasts of mild preeclempsia, severe cases and normal pregnancy group. (PMID:19487733)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	adipor2	ENSDARG00000101849
mus_musculus	Adipor2	ENSMUSG00000030168
rattus_norvegicus	Adipor2	ENSRNOG00000007990

Paralogs (10): MMD (ENSG00000108960), MMD2 (ENSG00000136297), PAQR5 (ENSG00000137819), ADIPOR1 (ENSG00000159346), PAQR6 (ENSG00000160781), PAQR4 (ENSG00000162073), PAQR3 (ENSG00000163291), PAQR8 (ENSG00000170915), PAQR7 (ENSG00000182749), PAQR9 (ENSG00000188582)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:93830) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 45 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased circulating HDL cholesterol level	2
abnormal glucose homeostasis	2
decreased circulating insulin level	2
decreased testis weight	2
decreased circulating cholesterol level	2
decreased susceptibility to diet-induced obesity	2
increased circulating adiponectin level	2
abnormal abdominal fat pad morphology	1
decreased circulating LDL cholesterol level	1
increased neutrophil cell number	1
small testis	1
seminiferous tubule degeneration	1
abnormal spermatogenesis	1
limb grasping	1
hyperglycemia	1
male infertility	1
increased circulating insulin level	1
abnormal lipid homeostasis	1
increased brain weight	1
decreased circulating triglyceride level	1
oligozoospermia	1
decreased pancreatic beta cell number	1
abnormal hormone level	1
decreased lean body mass	1
increased energy expenditure	1

+20 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Arabidopsis thaliana	Q9SVF3	98.1%	Diamond
Caenorhabditis elegans	Q94177	83.5%	Diamond
Caenorhabditis briggsae	A8WZU4	82.2%	Diamond
Oryza sativa Japonica Group	Q10PI5	70.9%	Diamond
Drosophila melanogaster	Q9VCY8	61.3%	Diamond
Saccharomyces cerevisiae S288C	Q03419	47.4%	Diamond
Eremothecium gossypii ATCC 10895	Q753H5	47.4%	Diamond
Schizosaccharomyces pombe 972h-	Q09749	43.1%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
FBXL14	protein-coding	144699
WNT5B	protein-coding	81029
MIR3649	ncRNA	100500816
CACNA2D4	protein-coding	93589
LRTM2	protein-coding	654429
LINC00940	ncRNA	100271702
DCP1B	protein-coding	196513
CACNA1C	protein-coding	775

Protein

Protein identifiers

Adiponectin receptor protein 2 — Q86V24 (reviewed: Q86V24)

Alternative names: Progestin and adipoQ receptor family member 2, Progestin and adipoQ receptor family member II

All UniProt accessions (1): Q86V24

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for ADIPOQ, an essential hormone secreted by adipocytes that regulates glucose and lipid metabolism. Required for normal body fat and glucose homeostasis. ADIPOQ-binding activates a signaling cascade that leads to increased PPARA activity, and ultimately to increased fatty acid oxidation and glucose uptake. Has intermediate affinity for globular and full-length adiponectin. Required for normal revascularization after chronic ischemia caused by severing of blood vessels.

Subunit / interactions. May form homooligomers and heterooligomers with ADIPOR1. Interacts with APPL2 (via BAR domain); ADIPOQ dissociates this interaction.

Subcellular location. Cell membrane.

Tissue specificity. Ubiquitous. Highly expressed in skeletal muscle, liver and placenta. Weakly expressed in brain, heart, colon, spleen, kidney, thymus, small intestine, peripheral blood leukocytes and lung.

Domain organisation. The N-terminus is cytoplasmic and the C-terminus is extracellular, contrary to what is observed for G protein-coupled receptors. Unlike G protein-coupled receptors, transmembrane helices are not kinked or tilted relative to the plane of the membrane.

Similarity. Belongs to the ADIPOR family.

RefSeq proteins (4): NP_001362292, NP_001362293, NP_001362294, NP_078827* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004254	AdipoR/HlyIII-related	Family

Pfam: PF03006

Enzyme classification (BRENDA)

• EC 3.5.1.23 — ceramidase (BRENDA: 26 organisms, 303 substrates, 355 inhibitors, 64 Km, 14 kcat entries)

Substrate kinetics (BRENDA)

43 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
N-LAUROYLSPHINGOSINE	0.149–0.4132	5
D-ERYTHRO-C12-4-NITROBENZO-2-OXA-1,3-DIAZOLE-CER	0.0393–0.0601	3
N-[12-[(7-NITRO-2-1,3-BENZOXADIAZOL-4-YL)AMINE]D	0.0155–0.066	3
(2R,3Z)-2-([(2E)-1-HYDROXY-12-[(7-NITRO-2,1,3-BE	0.087–0.19	2
N-[(2S,3R,4E)-1,3-DIHYDROXY-14-[(7-NITRO-2,1,3-B	0.193–0.204	2
N-[(2S,3R,4E)-1,3-DIHYDROXYNONADEC-4-EN-2-YL]-12	0.085–0.11	2
N-[(2S,3R,4E)-13-[[9-(ETHYLAMINO)-5-OXO-5H-BENZO	0.036–0.082	2
N-[(2S,3R,4E)-7-[[9-(DIETHYLAMINO)-5-OXO-5H-BENZ	0.1418–0.1818	2
(13E)-N-[(2S,3R,4E)-1,3-DIHYDROXY-7-[(2-OXO-2H-1	0.033	1
(15E)-N-[(2S,3R,4E)-1,3-DIHYDROXY-7-[(2-OXO-2H-1	0.04	1
(2R)-N-[(2S,3R,4E)-1,3-DIHYDROXY-7-[(2-OXO-2H-1-	0.042	1
(2S)-N-[(2S,3R,4E)-1,3-DIHYDROXY-7-[(2-OXO-2H-1-	0.021	1
(4E,2S,3R)-2-N-(10-PYRENEDECANOYL)-1,3,17-TRIHYD	0.0005	1
(9E)-N-[(2S,3R,4E)-1,3-DIHYDROXY-7-[(2-OXO-2H-1-	0.139	1
2,4-DIDEOXY-2-(HEXADECANOYLAMINO)-5-O-(2-OXO-2H-	0.016	1

UniProt features (51 total): helix 16, topological domain 8, transmembrane region 7, turn 5, mutagenesis site 4, binding site 3, sequence variant 2, strand 2, chain 1, region of interest 1, compositionally biased region 1, sequence conflict 1

Structure

Experimental structures (PDB)

8 structures by resolution:

PDB	Title	Method	Resolution (Å)
5LWY	Revised crystal structure of the human adiponectin receptor 2 in complex with a C18 free …	X-RAY DIFFRACTION	2.4
5LX9	CRYSTAL STRUCTURE OF HUMAN ADIPONECTIN RECEPTOR 2 IN COMPLEX WITH A C18 FREE FATTY ACID …	X-RAY DIFFRACTION	2.4
6KS1	Crystal structure of the human adiponectin receptor 2	X-RAY DIFFRACTION	2.4
6YX9	Cryogenic human adiponectin receptor 2 (ADIPOR2) at 2.4 A resolution determined by Serial …	X-RAY DIFFRACTION	2.4
6YXD	Room temperature structure of human adiponectin receptor 2 (ADIPOR2) at 2.9 A resolution …	X-RAY DIFFRACTION	2.9
5LXA	CRYSTAL STRUCTURE OF HUMAN ADIPONECTIN RECEPTOR 2 IN COMPLEX WITH A C18 FREE FATTY ACID …	X-RAY DIFFRACTION	3
6YXG	Cryogenic human adiponectin receptor 2 (ADIPOR2) with Tb-XO4 ligand determined by Serial …	X-RAY DIFFRACTION	3.01
6YXF	Cryogenic human adiponectin receptor 2 (ADIPOR2) with Gd-DO3 ligand determined by Serial …	X-RAY DIFFRACTION	3.02

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86V24-F1	82.69	0.70

Antibody-complex structures (SAbDab)

8 antibodies co-crystallized with this protein: 5LWY, 5LX9, 5LXA, 6KS1, 6YX9, 6YXD, 6YXF, 6YXG

Human Protein Atlas

Protein class: Transporters, Transporter channels and pores, Predicted membrane proteins

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3)

Position	Role
202	Zn(2+)
348	Zn(2+)
352	Zn(2+)

Mutagenesis-validated functional residues (4)

Position	Phenotype
202	abolishes response to adipoq binding; when associated with a-219; a-348 and a-352.
219	impairs response to adipoq binding. abolishes response to adipoq binding; when associated with a-202; a-348 and a-352.
348	impairs response to adipoq binding. abolishes response to adipoq binding; when associated with a-202; a-219 and a-352.
352	abolishes response to adipoq binding; when associated with a-202; a-219 and a-348.

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-163680	AMPK inhibits chREBP transcriptional activation activity	curated
R-HSA-163685	Integration of energy metabolism	—
R-HSA-1430728	Metabolism	—

MSigDB gene sets: 293 (showing top): GOBP_LIPID_MODIFICATION, MODULE_52, KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY, PAX4_01, MODULE_255, GOBP_RESPONSE_TO_PEPTIDE, TGCACTT_MIR519C_MIR519B_MIR519A, MODULE_151, ATACCTC_MIR202, ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, MODULE_317, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_WOUND_HEALING, CAIRO_HEPATOBLASTOMA_CLASSES_DN, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY

GO Biological Process (8): hormone-mediated signaling pathway (GO:0009755), fatty acid oxidation (GO:0019395), adiponectin-activated signaling pathway (GO:0033211), glucose homeostasis (GO:0042593), vascular wound healing (GO:0061042), positive regulation of cold-induced thermogenesis (GO:0120162), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (6): signaling receptor activity (GO:0038023), identical protein binding (GO:0042802), metal ion binding (GO:0046872), adiponectin binding (GO:0055100), adipokinetic hormone receptor activity (GO:0097003), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Integration of energy metabolism	1
Metabolism	1

GO top-level categories

25 GO namespaces:

Category	Terms
protein binding	2
signal transduction	1
cellular response to hormone stimulus	1
fatty acid metabolic process	1
lipid oxidation	1
hormone-mediated signaling pathway	1
cytokine-mediated signaling pathway	1
carbohydrate homeostasis	1
angiogenesis involved in wound healing	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
molecular transducer activity	1
cation binding	1
hormone binding	1
protein-hormone receptor activity	1
adiponectin binding	1
adipokinetic hormone binding	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 4 of 16 annotations. The rest are phylogenetic / computational / electronic (IEA).

4 experimentally-supported GO terms:

GO term	NS	Evidence
adiponectin-activated signaling pathway	BP	direct assay
plasma membrane	CC	direct assay
adipokinetic hormone receptor activity	MF	direct assay
adiponectin binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 824 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADIPOR2	ADIPOQ	Q15848	946
ADIPOR2	PPARA	Q07869	900
ADIPOR2	CDH13	P55290	753
ADIPOR2	APPL1	Q9UKG1	726
ADIPOR2	LEP	P41159	723
ADIPOR2	INS	P01308	714
ADIPOR2	CAMKK2	Q96RR4	669
ADIPOR2	PPARGC1A	Q9UBK2	662
ADIPOR2	SIRT1	Q96EB6	615
ADIPOR2	PPARG	P37231	612
ADIPOR2	RETN	Q9HD89	584
ADIPOR2	LEPR	P48357	581
ADIPOR2	RETNLB	Q9BQ08	573
ADIPOR2	SREBF1	P36956	553
ADIPOR2	NAMPT	P43490	511

IntAct

Human interaction partners of ADIPOR2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
TMBIM6	physical association	0.560	3
NCK1	association	0.350	1
NCK2	association	0.350	1
APPL1	proximity	0.270	3

BioGRID (131 interactions; top human partners by supporting records): PTPLAD1 (Affinity Capture-MS; 3 records), RNF181 (Affinity Capture-MS; 3 records), APPL1 (Two-hybrid; 2 records), GGT7 (Affinity Capture-MS; 2 records), NCK1 (Affinity Capture-MS; 2 records), RNF145 (Affinity Capture-Western; 2 records), ACSL4 (Co-localization), ADIPOR1 (Affinity Capture-Western), ALDH3A2 (Affinity Capture-MS), ALDOC (Affinity Capture-MS), ANXA2 (Affinity Capture-MS), APRT (Affinity Capture-MS), ARG1 (Affinity Capture-MS), ARL6IP5 (Affinity Capture-MS), ARPC2 (Affinity Capture-MS)

SIGNOR signaling

showing 2 of 3 signaling interactions:

A	Effect	B	Mechanism
ADIPOQ	up-regulates	ADIPOR2	binding
ADIPOR2	up-regulates	APPL1	binding

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
ADIPOR1;ADIPOR2

Disease & clinical

Genetic variants

Variant evidence for ADIPOR2: 71 ClinVar records (23 pathogenic / likely pathogenic); 3 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

71 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	22
Likely pathogenic	1
Uncertain significance	22
Likely benign	13
Benign	0

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 23 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
57044	GRCh38/hg38 12p13.33-13.32(chr12:121255-3968447)x1	Pathogenic	criteria provided, single submitter	1
58952	GRCh38/hg38 12p13.33(chr12:99592-1786491)x1	Pathogenic	criteria provided, single submitter	1
59798	GRCh38/hg38 12p13.33-13.32(chr12:199896-3284963)x3	Pathogenic	criteria provided, single submitter	1
253551	GRCh37/hg19 12p13.33-13.32(chr12:222888-3931052)x1	Pathogenic	criteria provided, single submitter	1
1809216	GRCh37/hg19 12p13.33(chr12:817514-2205439)x1	Pathogenic	criteria provided, single submitter	1
2685429	GRCh37/hg19 12p13.33-13.32(chr12:191243-5332596)x1	Pathogenic	criteria provided, single submitter	1
4884760	GRCh37/hg19 12p13.33-13.32(chr12:230421-3358023)x1	Pathogenic	criteria provided, single submitter	1
3024578	GRCh37/hg19 12p13.33(chr12:922808-2129821)x1	Likely pathogenic	criteria provided, single submitter	1
147092	GRCh38/hg38 12p13.33(chr12:54452-2558097)x1	Pathogenic	no assertion criteria provided	1
147690	GRCh38/hg38 12p13.33-13.31(chr12:199896-5807366)x1	Pathogenic	no assertion criteria provided	1
148625	GRCh38/hg38 12p13.33(chr12:80412-2850599)x1	Pathogenic	no assertion criteria provided	1
149561	GRCh38/hg38 12p13.33-13.32(chr12:80412-4420585)x1	Pathogenic	no assertion criteria provided	1
152450	GRCh38/hg38 12p13.33-13.32(chr12:54427-4004912)x1	Pathogenic	no assertion criteria provided	1
152732	GRCh38/hg38 12p13.33-13.32(chr12:54427-3639603)x1	Pathogenic	no assertion criteria provided	1
154528	GRCh38/hg38 12p13.33(chr12:121255-3003320)x1	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore ADIPOR2’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 43 predictions of 1,259):

Position(s)	Effect	Δscore	Sites
12:1772840–1772841	acceptor_loss	1.0000	6
12:1772962–1772963	donor_loss	1.0000	4
12:1784074–1784075	donor_loss	1.0000	5
12:1777852–1777853	acceptor_loss	0.9900	6
12:1778026–1778027	donor_loss	0.9900	5
12:1778325	donor_gain	0.9900
12:1780449–1780450	acceptor_loss	0.9900	6
12:1780638–1780639	donor_loss	0.9900	4
12:1781077–1781078	donor_loss	0.9900	5
12:1783851	acceptor_gain	0.9900

AlphaMissense

1,306 missense substitutions predicted likely pathogenic (of 2,557 scored), across 278 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M317	9	0.979	0.999
D219	8	1.000	1.000
H202	8	0.999	1.000
H348	8	0.999	1.000
H352	8	0.999	1.000
H143	8	0.998	0.999
D117	8	0.997	0.999
H152	8	0.997	0.999
F351	8	0.996	0.999
N148	8	0.994	1.000
H207	8	0.994	0.999
D342	8	0.994	0.999
N118	8	0.990	1.000
H362	8	0.990	0.999
F282	8	0.989	1.000
F269	8	0.987	0.999
H125	8	0.986	1.000
F159	8	0.971	0.994
S138	8	0.969	1.000
F215	8	0.968	0.995

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	5.97e-05
Lung Adenocarcinoma (TCGA)	unfavorable	0.000449
Kidney Chromophobe (TCGA)	unfavorable	0.000705

Disease associations

OMIM: gene MIM:607946 | disease phenotypes:

GWAS associations

3 associations:

Study	Trait	p-value
GCST90002404_504	Red cell distribution width	7e-11
GCST001431_6	Adverse response to lamotrigine and phenytoin	3e-6
GCST002830_19	Urate levels in lean individuals	5e-6

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3392947 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Adiponectin receptors

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
AdipoRon	Agonist	5.51	pKd

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL3393145	KD	1800 nM

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.51	Kd	3100	nM	CHEMBL3393145

PubChem BioAssay actives

1 with measured affinity, of 1 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(4-benzoylphenoxy)-N-(1-benzylpiperidin-4-yl)acetamide	1189230: Binding affinity to AdipoR2 (unknown origin) by surface plasmon resonance analysis	kd	3.1000	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, decreases expression, increases expression	3
Air Pollutants	decreases expression, increases abundance, increases expression	2
Arsenic	increases abundance, increases expression, affects methylation	2
Progesterone	affects cotreatment, increases expression	2
MRI-1867	affects cotreatment, decreases expression, decreases reaction	1
parthenolide	affects binding, increases activity	1
taxifolin	increases activity, affects binding	1
bisphenol A	decreases methylation	1
trichostatin A	affects expression	1
osteum	decreases reaction, affects cotreatment, decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
sodium arsenite	increases expression, increases abundance	1
schizandrin A	affects binding, increases activity	1
CGP 52608	affects binding, increases reaction	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
PCI 5002	affects cotreatment, increases expression	1
Rosiglitazone	increases activity, increases reaction, decreases reaction, increases expression	1
Leflunomide	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Catechin	affects cotreatment, increases expression	1
Dexamethasone	increases activity, increases reaction	1
Methotrexate	increases expression	1
Paraquat	decreases reaction, increases expression	1
Pesticides	decreases methylation	1
Phthalic Acids	decreases methylation	1
Piroxicam	decreases expression	1
Smoke	increases expression, increases abundance	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3395076	Binding	Binding affinity to AdipoR2 (unknown origin) by surface plasmon resonance analysis	Small molecule adenosine 5’-monophosphate activated protein kinase (AMPK) modulators and human diseases. — *J Med Chem*

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C3G1	HEK293T AdipoR2 KO	Transformed cell line	Female
CVCL_SB72	HAP1 ADIPOR2 (-) 1	Cancer cell line	Male
CVCL_XL12	HAP1 ADIPOR2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for ADIPOR2 across ~30M SureChEMBL compounds — explore on Sugi Predict.